Background: There has been a protracted effort to identify reliable targets for migraine. It is believed that each year, hundreds of millions of individuals worldwide suffer from migraines, making this widespread neurological ailment the second leading cause of years of disability worldwide. The rationale of this study is to identify the major targets involved in migraine attacks.
Methods: For this review, specialized databases were searched, such as PubMed, EMBASE, DynaMed Plus, and Science Direct databases that included the pathophysiological mechanisms of migraine, focusing on in vitro and in vivo studies in the clinical management of migraine.
Results: Calcitonin gene-related peptide, Pituitary adenylate cyclase-activating polypeptide (PACAP), NOD-like receptor Protein (NLRP3), Serotonin, and some other neuroinflammatory biomarkers are collectively responsible for the cerebral blood vessel dilation and involved in the nociceptive pain which leads to migraine attack.
Conclusion: Migraine biomarkers such as CGRP, PACAP, NLRP3, Nitric oxide synthase, MMP9, and Serotonin could be targets for developing drugs. Present marketed medications temporarily reduce symptoms and pain and have serious cardiovascular side effects. It is suggested that herbal treatment may help prevent migraine attacks without adverse effects. Natural biomolecules that may give better treatment than the present marketed medication and full fledge research should be carried out with natural biomarkers by the Network Pharmacological approach.
[http://dx.doi.org/10.1212/01.WNL.0000036617.04943.96] [PMID: 12473779]
[http://dx.doi.org/10.1111/j.1526-4610.2011.02040.x] [PMID: 22103661]
[http://dx.doi.org/10.1111/j.1468-1331.2006.01415.x] [PMID: 16930369]
[http://dx.doi.org/10.1111/j.1526-4610.2009.01570.x] [PMID: 19925624]
[http://dx.doi.org/10.1016/j.pharmthera.2012.12.007] [PMID: 23333322]
[http://dx.doi.org/10.1046/j.1365-2362.2000.00633.x] [PMID: 10759887]
[http://dx.doi.org/10.1046/j.1468-2982.2002.00310.x] [PMID: 11993614]
[http://dx.doi.org/10.1146/annurev-pharmtox-010814-124701] [PMID: 25340934]
[http://dx.doi.org/10.3389/fnins.2019.01281] [PMID: 31866806]
[http://dx.doi.org/10.1016/j.bcp.2018.04.024] [PMID: 29704474]
[http://dx.doi.org/10.1111/head.13802] [PMID: 32293721]
[http://dx.doi.org/10.1046/j.1468-2982.2002.00304.x] [PMID: 11993611]
[http://dx.doi.org/10.1046/j.1468-2982.1995.1506489.x] [PMID: 8706112]
[http://dx.doi.org/10.1111/j.1526-4610.2006.00722.x] [PMID: 17635596]
[http://dx.doi.org/10.1186/s10194-022-01465-1] [PMID: 35927625]
[http://dx.doi.org/10.1111/j.1526-4610.2009.01523.x] [PMID: 19788468]
[http://dx.doi.org/10.2165/11534920-000000000-00000] [PMID: 20433208]
[http://dx.doi.org/10.1111/j.1526-4610.2010.01657.x] [PMID: 20353434]
[http://dx.doi.org/10.1016/S1474-4422(22)00185-5] [PMID: 35716692]
[http://dx.doi.org/10.1111/head.14391] [PMID: 36286602]
[http://dx.doi.org/10.1080/01616412.2021.1981105] [PMID: 35037597]
[http://dx.doi.org/10.1016/j.compbiomed.2022.105389] [PMID: 35303581]
[http://dx.doi.org/10.19082/6430] [PMID: 29765566]